Zou et al. demonstrated that miR-630 decreased cell proliferation and increased ovarian cancer cells (A2780 and SKOV3) sensitivity to cisplatin, due to its ability to modulate phosphatase and tensin homolog (PTEN) expression in these cells [81]. Here, PTEN is linked to ovarian carcinoma.